| Literature DB >> 33000143 |
Katharine H D Crawford1,2,3, Adam S Dingens1, Rachel Eguia1, Caitlin R Wolf4, Naomi Wilcox4, Jennifer K Logue4, Kiel Shuey4, Amanda M Casto4, Brooke Fiala5,6, Samuel Wrenn5,6, Deleah Pettie5,6, Neil P King5,6, Alexander L Greninger7,8, Helen Y Chu4, Jesse D Bloom1,2,9.
Abstract
Most individuals infected with SARS-CoV-2 develop neutralizing antibodies that target the viral spike protein. Here we quantify how levels of these antibodies change in the months following SARS-CoV-2 infection by examining longitudinal samples collected between ~30 and 152 days post symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about four-fold from one to four months post symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B-cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.Keywords: COVID-19; RBD; SARS-CoV-2; antibody dynamics; neutralizing antibodies; spike
Year: 2020 PMID: 33000143 PMCID: PMC7543487 DOI: 10.1093/infdis/jiaa618
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226